Navigation Links
Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
Date:4/16/2008

QUEBEC CITY, April 16 /PRNewswire-FirstCall/ - Victhom Human Bionics Inc. (Victhom, TSX: VHB) today disclosed initial results from the ongoing human clinical trial of its Closed-Loop neuromodulation System (CLS) used in the Neurostep(TM) for the treatment of patients suffering from foot drop secondary to a central nervous system lesion. According to the Company, the initial results of the trial have demonstrated that the Neurostep(TM) is capable of collecting sensory signals from a nerve and of stimulating the appropriate muscle groups, which represents, to the knowledge of the Company, the world's first proof of concept in a human clinical trial of a CLS product used on peripheral nerves.

The ongoing human clinical trial on the Neurostep(TM) has two major objectives. The first objective is to evaluate the sensing and stimulation mechanisms of the product. The initial results suggest that the Neurostep(TM) is capable of collecting sensory signals from a nerve located in the thigh. The interim results also demonstrate the capacity of the Neurostep(TM), based on the information collected from the nerve, to stimulate the appropriate muscle group to lift the foot in the desired direction and in synchronization with the patient's gait.

The Company expects to announce later this year results on the second major objective of the trial aimed at evaluating the efficacy of the Neurostep (TM) in providing clinically measurable benefits, such as helping patients to walk faster and over longer distances.

Mr. Nader Kameli, Chief Operating Officer of the Neurobionix division, said: "We are excited about the initial results coming out of the clinical trial, which further increase our confidence in the ability of the closed-loop technology to open the door to next generation products in the neuromodulation industry that can deliver therapy to patients in a more effective manner than the continuous or pre-programmed stimulation regimen delivered by current generation devices". Mr. Kameli also stated: "With these promising initial results on the CLS platform proof of concept in humans, Victhom is well positioned to leverage its unique technology for the development of new exciting indications".

The Neurostep(TM), a fully implantable investigational neuromodulation product designed to treat gait disorders (e.g., foot drop), is the first CLS product aimed at using the patient's own nervous system as the source for detection of intention to move and control their leg. Contrary to other systems that use surrogates such as external sensors, the Neurostep(TM) detects intrinsic muscle activities and surface sensation events from the nerve signals delivered to the spine and brain. This information is then used as the trigger for intervention through neurostimulation, as needed, to complete function.

About Victhom

Victhom discovers, develops and manufactures bionic devices involved in the treatment of a variety of physical and physiological dysfunctions. Victhom's Neurobionix business unit focuses on the development and commercialization of technologies and products involving implantable devices that feature neurosensing and neurostimulation components, integrated with artificial intelligence. Victhom's Biotronix business unit develops biomechatronic products to support or replace peripheral limbs in what is known as the orthotics and prosthetics market.


'/>"/>
SOURCE VICTHOM HUMAN BIONICS INC.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma
2. EMD Serono Announces Planned Investment of $50 Million in Research Center in Massachusetts
3. Angiotech announces director resignation
4. BioHorizons Announces the Purchase of Implant Logic Systems
5. CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
6. Arpida Announces Conference Call on 17 April
7. Arpida Announces Agenda Items for Shareholders Meeting
8. BioMed Realty Trust Announces Retirement of Mark Riedy From Its Board of Directors
9. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
10. Boston Scientific Announces Japanese Approval of Heart Failure Lead
11. Vasogen Announces Implementation of Strategic Restructuring Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published ... the peer-reviewed journal from touchONCOLOGY, Andrew D ... cost of cancer care is placing an increasing ... of expensive biologic therapies. With the patents on ...
(Date:6/23/2016)... Connecticut (PRWEB) , ... June 23, 2016 , ... ... introduce a new line of intelligent tools designed, tuned and optimized exclusively for ... September 12–17 in Chicago. The result of a collaboration among several companies with ...
(Date:6/22/2016)... Research and Markets has announced the addition of the ... The global biomarkers market ... 2013. The market is expected to grow at a five-year compound ... from $50.6 billion in 2015 to $96.6 billion in 2020. ... (2015 to 2020) are discussed. As well, new products approved in ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016   ... the first pluripotent stem cell-derived islet replacement therapy for ... two presentations at ISSCR 2016 Annual Meeting.  ISSCR 2016, ... 22nd to 25th at Moscone West in San Francisco.  ... Details of the presentations are as follows:Event: , Focus ...
Breaking Biology Technology:
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):